Itacitinib
Phase 3Small molecule
IncyteItacitinib is an experimental drug being studied to treat blood cancers and certain immune system disorders by blocking proteins that help cancer cells or abnormal immune cells grow.[1] Itacitinib is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Itacitinib is one of 89 small molecule programs targeting Classical Hodgkin Lymphoma. It is currently in Phase 3.
5
Indications
47
Total Trials
7
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Neoral
NovartisApproved
Medrol
PfizerApproved
Selzentry
GSKApproved
Nipent
PfizerApproved
Defitelio
Jazz PharmaceuticalsApproved
Gleevec
NovartisApproved
Olumiant
Eli LillyApproved
Qvar
SSchering-Plough
Approved
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Graft Versus Host Disease4 trials
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
Terminated·—·Phase 1·NCT04070781·1 enrolled
Myelofibrosis4 trials
Graft Versus Host Disease4 trials
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
Active, not recruiting·—·Phase 2·NCT05364762·20 enrolled
Advanced Solid Tumors3 trials
Non-Small Cell Lung Cancer3 trials
26 more indications
Bronchiolitis Obliterans2 trials
Chronic Graft Versus Host Disease2 trials
Diffuse Large B-Cell Lymphoma2 trials
Psoriasis1 trial
Rheumatoid Arthritis1 trial
Cytokine Release Syndrome1 trial
T-Cell Prolymphocytic Leukemia1 trial
Overlap Syndrome1 trial
B-cell Malignancies1 trial
Immunotherapy1 trial
Function1 trial
Transplantation1 trial
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT05823571·32 enrolled
Lymphoma1 trial
Ulcerative Colitis1 trial
Immune Checkpoint Inhibitors1 trial
Prophylaxis1 trial
Corticosteroids1 trial
Refractory Metastatic1 trial
Small Cell Lung Cancer1 trial
First-line Treatment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Itacitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]